Pathways , and IL-15 Β
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
T Cell Binding to Activated Dendritic Cells Cutting Edge
Cutting Edge: CCR4 Mediates Antigen-Primed T Cell Binding to Activated Dendritic Cells Meng-tse Wu, Hui Fang and Sam T. Hwang This information is current as J Immunol 2001; 167:4791-4795; ; of September 27, 2021. doi: 10.4049/jimmunol.167.9.4791 http://www.jimmunol.org/content/167/9/4791 Supplementary http://www.jimmunol.org/content/suppl/2001/10/11/167.9.4791.DC1 Downloaded from Material References This article cites 32 articles, 13 of which you can access for free at: http://www.jimmunol.org/content/167/9/4791.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 27, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2001 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. ● Cutting Edge: CCR4 Mediates Antigen-Primed T Cell Binding to Activated Dendritic Cells Meng-tse Wu, Hui Fang, and Sam T. Hwang1 DC. In the periphery, activated, Ag-bearing DC may bind to cog- The binding of a T cell to an Ag-laden dendritic cell (DC) is a nate effector memory T cells (mTC). -
Type I Interferons and the Development of Impaired Vascular Function and Repair in Human and Murine Lupus
Type I Interferons and the Development of Impaired Vascular Function and Repair in Human and Murine Lupus by Seth G Thacker A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Immunology) in The University of Michigan 2011 Doctoral Committee: Associate Professor Mariana J. Kaplan, Chair Professor David A. Fox Professor Alisa E. Koch Professor Matthias Kretzler Professor Nicholas W. Lukacs Associate Professor Daniel T. Eitzman © Seth G Thacker 2011 Sharon, this work is dedicated to you. This achievement is as much yours as it is mine. Your support through all six years of this Ph.D. process has been incredible. You put up with my countless miscalculations on when I would finish experiments, and still managed to make me and our kids feel loved and special. Without you this would have no meaning. Sharon, you are the safe harbor in my life. ii Acknowledgments I have been exceptionally fortunate in my time here at the University of Michigan. I have been able to interact with so many supportive people over the years. I would like to express my thanks and admiration for my mentor. Mariana has taught me so much about writing, experimental design and being a successful scientist in general. I could never have made it here without her help. I would also like to thank Mike Denny. He had a hand in the beginning of all of my projects in one way or another, and was always quick and eager to help in whatever way he could. He really made my first year in the lab successful. -
Mechanism of Macrophage-Derived Chemokine/CCL22 Production by Hacat Keratinocytes
C Yano, et al Ann Dermatol Vol. 27, No. 2, 2015 http://dx.doi.org/10.5021/ad.2015.27.2.152 ORIGINAL ARTICLE Mechanism of Macrophage-Derived Chemokine/CCL22 Production by HaCaT Keratinocytes Chizuko Yano, Hidehisa Saeki1, Mayumi Komine2, Shinji Kagami3, Yuichiro Tsunemi4, Mamitaro Ohtsuki2, Hidemi Nakagawa Department of Dermatology, The Jikei University School of Medicine, 1Department of Dermatology, Nippon Medical School, Tokyo, 2Department of Dermatology, Jichi Medical University, Shimotsuke, 3Department of Dermatology, Kanto Central Hospital, 4Department of Dermatology, Tokyo Women’s Medical University, Tokyo, Japan Background: CC chemokine ligand 17 (CCL17) and CCL22 27(2) 152∼156, 2015) are the functional ligands for CCR4. We previously reported that inhibitors of nuclear factor-kappa B and p38 mi- -Keywords- togen-activated protein kinase (p38 MAPK), but not of ex- Chemokine CCL22, Chemokine CCL17, Epidermal growth tracellular signal-related kinase (ERK), inhibited tumor ne- factor receptor, HaCaT keratinocytes crosis factor (TNF)-α- and interferon (IFN)-γ-induced pro- duction of CCL17 by the human keratinocyte cell line, HaCaT. Further, an inhibitor of epidermal growth factor re- INTRODUCTION ceptor (EGFR) enhanced the CCL17 production by these keratinocytes. Objective: To identify the mechanism under- The macrophage-derived chemokine (MDC)/CC chemo- lying CCL22 production by HaCaT cells. Methods: We inves- kine ligand 22 (CCL22) is one of the functional ligands for tigated the signal transduction pathways by which TNF-α CC chemokine receptor 4 (CCR4) and is a chemoattractant and IFN-γ stimulate HaCaT cells to produce CCL22 by add- for the CCR4-expressing cells such as Th2 cells. We and ing various inhibitors. -
Differential Expression of Interferon-Γ and Chemokine Genes
Differential expression of interferon-γ and chemokine genes distinguishes Rasmussen encephalitis from cortical dysplasia and provides evidence for an early Th1 immune response Owens et al. Owens et al. Journal of Neuroinflammation 2013, 10:56 http://www.jneuroinflammation.com/content/10/1/56 Owens et al. Journal of Neuroinflammation 2013, 10:56 JOURNAL OF http://www.jneuroinflammation.com/content/10/1/56 NEUROINFLAMMATION RESEARCH Open Access Differential expression of interferon-γ and chemokine genes distinguishes Rasmussen encephalitis from cortical dysplasia and provides evidence for an early Th1 immune response Geoffrey C Owens1,7*, My N Huynh1, Julia W Chang1, David L McArthur1, Michelle J Hickey2, Harry V Vinters2,3, Gary W Mathern1,4,5,6† and Carol A Kruse1,6† Abstract Background: Rasmussen encephalitis (RE) is a rare complex inflammatory disease, primarily seen in young children, that is characterized by severe partial seizures and brain atrophy. Surgery is currently the only effective treatment option. To identify genes specifically associated with the immunopathology in RE, RNA transcripts of genes involved in inflammation and autoimmunity were measured in brain tissue from RE surgeries and compared with those in surgical specimens of cortical dysplasia (CD), a major cause of intractable pediatric epilepsy. Methods: Quantitative polymerase chain reactions measured the relative expression of 84 genes related to inflammation and autoimmunity in 12 RE specimens and in the reference group of 12 CD surgical specimens. Data were analyzed by consensus clustering using the entire dataset, and by pairwise comparison of gene expression levels between the RE and CD cohorts using the Harrell-Davis distribution-free quantile estimator method. -
The Combination of IL-12 and IL-18 NK/T-NK Cells Derived with IL-2, IL-15
Cytokine Production and Killer Activity of NK/T-NK Cells Derived with IL-2, IL-15, or the Combination of IL-12 and IL-18 This information is current as Bernard R. Lauwerys, Nathalie Garot, Jean-Christophe of September 28, 2021. Renauld and Frédéric A. Houssiau J Immunol 2000; 165:1847-1853; ; doi: 10.4049/jimmunol.165.4.1847 http://www.jimmunol.org/content/165/4/1847 Downloaded from References This article cites 31 articles, 17 of which you can access for free at: http://www.jimmunol.org/content/165/4/1847.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 28, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2000 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Cytokine Production and Killer Activity of NK/T-NK Cells Derived with IL-2, IL-15, or the Combination of IL-12 and IL-181 Bernard R. Lauwerys,* Nathalie Garot,* Jean-Christophe Renauld,†‡ and Fre´de´ric A. -
Interleukin-18 in Health and Disease
International Journal of Molecular Sciences Review Interleukin-18 in Health and Disease Koubun Yasuda 1 , Kenji Nakanishi 1,* and Hiroko Tsutsui 2 1 Department of Immunology, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan; [email protected] 2 Department of Surgery, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan; [email protected] * Correspondence: [email protected]; Tel.: +81-798-45-6573 Received: 21 December 2018; Accepted: 29 January 2019; Published: 2 February 2019 Abstract: Interleukin (IL)-18 was originally discovered as a factor that enhanced IFN-γ production from anti-CD3-stimulated Th1 cells, especially in the presence of IL-12. Upon stimulation with Ag plus IL-12, naïve T cells develop into IL-18 receptor (IL-18R) expressing Th1 cells, which increase IFN-γ production in response to IL-18 stimulation. Therefore, IL-12 is a commitment factor that induces the development of Th1 cells. In contrast, IL-18 is a proinflammatory cytokine that facilitates type 1 responses. However, IL-18 without IL-12 but with IL-2, stimulates NK cells, CD4+ NKT cells, and established Th1 cells, to produce IL-3, IL-9, and IL-13. Furthermore, together with IL-3, IL-18 stimulates mast cells and basophils to produce IL-4, IL-13, and chemical mediators such as histamine. Therefore, IL-18 is a cytokine that stimulates various cell types and has pleiotropic functions. IL-18 is a member of the IL-1 family of cytokines. IL-18 demonstrates a unique function by binding to a specific receptor expressed on various types of cells. -
BAFF Suppresses IL-15 Expression in B Cells
BAFF Suppresses IL-15 Expression in B Cells Ning Ma, Chen Xing, He Xiao, Youdi He, Gencheng Han, Guojiang Chen, Chunmei Hou, Bernadette Marrero, Yujuan Wang, Shengquan Zhang, Beifen Shen, Yan Li and Renxi This information is current as Wang of September 28, 2021. J Immunol 2014; 192:4192-4201; Prepublished online 26 March 2014; doi: 10.4049/jimmunol.1302132 http://www.jimmunol.org/content/192/9/4192 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2014/03/26/jimmunol.130213 Material 2.DCSupplemental http://www.jimmunol.org/ References This article cites 39 articles, 14 of which you can access for free at: http://www.jimmunol.org/content/192/9/4192.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 28, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology BAFF Suppresses IL-15 Expression in B Cells Ning Ma,*,†,1 Chen Xing,*,1 He Xiao,*,1 Youdi He,‡ Gencheng Han,* Guojiang Chen,* Chunmei Hou,* Bernadette Marrero,x Yujuan Wang,{ Shengquan Zhang,‖ Beifen Shen,* Yan Li,* and Renxi Wang* Clinical trials have shown that BAFF inhibitors do not reduce memory B cell levels but can reduce the number of mature B cells. -
Evolutionary Divergence and Functions of the Human Interleukin (IL) Gene Family Chad Brocker,1 David Thompson,2 Akiko Matsumoto,1 Daniel W
UPDATE ON GENE COMPLETIONS AND ANNOTATIONS Evolutionary divergence and functions of the human interleukin (IL) gene family Chad Brocker,1 David Thompson,2 Akiko Matsumoto,1 Daniel W. Nebert3* and Vasilis Vasiliou1 1Molecular Toxicology and Environmental Health Sciences Program, Department of Pharmaceutical Sciences, University of Colorado Denver, Aurora, CO 80045, USA 2Department of Clinical Pharmacy, University of Colorado Denver, Aurora, CO 80045, USA 3Department of Environmental Health and Center for Environmental Genetics (CEG), University of Cincinnati Medical Center, Cincinnati, OH 45267–0056, USA *Correspondence to: Tel: þ1 513 821 4664; Fax: þ1 513 558 0925; E-mail: [email protected]; [email protected] Date received (in revised form): 22nd September 2010 Abstract Cytokines play a very important role in nearly all aspects of inflammation and immunity. The term ‘interleukin’ (IL) has been used to describe a group of cytokines with complex immunomodulatory functions — including cell proliferation, maturation, migration and adhesion. These cytokines also play an important role in immune cell differentiation and activation. Determining the exact function of a particular cytokine is complicated by the influence of the producing cell type, the responding cell type and the phase of the immune response. ILs can also have pro- and anti-inflammatory effects, further complicating their characterisation. These molecules are under constant pressure to evolve due to continual competition between the host’s immune system and infecting organisms; as such, ILs have undergone significant evolution. This has resulted in little amino acid conservation between orthologous proteins, which further complicates the gene family organisation. Within the literature there are a number of overlapping nomenclature and classification systems derived from biological function, receptor-binding properties and originating cell type. -
Plasma Macrophage-Derived Chemokine (CCL22) and Its
Egypt J Pediatr Allergy Immunol 2005; 3(1): 20-31. Original article Plasma macrophage-derived chemokine (CCL22) and its receptor CCR4 on peripheral blood T lymphocytes of asthmatic children Background: The macrophage-derived chemokine (MDC/CCL22) acts on Mohamed H. Ezzat, CC chemokine receptor-4 (CCR4) to direct trafficking and recruitment of T Karim Y. Shaheen*. helper-2 (TH2) cells into sites of allergic inflammation. It was previously found overexpressed in lesional samples from adult asthmatics. Objective: This study is aimed to investigate the participation of CCR4/MDC axis in the development of TH2-dominated allergen-induced From the Departments childhood asthma in relation to disease activity, attack severity, and of Pediatrics and response to therapy, and to outline its value in differentiating atopic asthma Clinical Pathology*, from infection-associated airway reactivity. Faculty of Medicine, Methods: Proportion of CCR4-expressing peripheral blood T lymphocytes Ain Shams University, + (CCR4 PBTL%) were purified and quantitated by negative selection from Cairo, Egypt. peripheral blood mononuclear cells by flow cytometry, and the concentration of MDC in plasma was measured by ELISA in 32 children with atopic asthma (during exacerbation and remission), as well as in 12 children with acute lower respiratory tract infections (ALRTI), and 20 healthy children serving as controls. Results: The mean plasma MDC level (925±471.5 pg/ml) and CCR4+PBTL% (55.3±23.6%) were significantly higher in asthmatic children during acute attacks in comparison to children with ALRTI (109±27.3 pg/ml and 27.6±7.5%) and healthy controls (99.6±25.6 pg/ml and 24.2±4.1%). -
The Efficacy of Etanercept As Anti-Breast Cancer Treatment Is
Shirmohammadi et al. BMC Cancer (2020) 20:836 https://doi.org/10.1186/s12885-020-07228-y RESEARCH ARTICLE Open Access The efficacy of etanercept as anti-breast cancer treatment is attenuated by residing macrophages Elnaz Shirmohammadi1, Seyed-Esmaeil Sadat Ebrahimi1, Amir Farshchi2 and Mona Salimi3* Abstract Background: Interaction between microenvironment and breast cancer cells often is not considered at the early stages of drug development leading to failure of many drugs at later clinical stages. Etanercept is a TNF-alpha inhibitor that has been investigated for potential antitumor effect in breast cancer with conflicting results. Methods: Secretome data on MDA-MB-231 cancer cell-line were from public repositories and subjected to gene enrichment analyses. Since MDA-MB-231 cells secrete high levels of Granulocyte-Monocyte Colony Stimulating Factor, which activates macrophages to promote tumor growth, the effect of macrophage co-culturing on anticancer efficacy of Etanercept in breast cancer was evaluated using the Boolean network modeling and in vitro experiments including invasion, cell cycle, Annexin PI, and tetrazolium based viability assays and NFKB activity. Results: The secretome profile of MDA-MB-231 cells was similar to the expression of genes following treatment of breast cancer cells with TNF-α. Accordingly, inhibition of TNF-α by Etanercept decreased MDA-MB-231 cell survival, induced apoptosis and cell cycle arrest in vitro and inhibited NFKB activation. The inhibitory effect of Etanercept on cell viability, cell cycle progression, invasion and induction of apoptosis decreased following co-culturing of the cancer cells with macrophages. The Boolean network modeling of the changes in the dynamics of intracellular signaling pathways revealed NFKB activation by secretome of macrophages, leading to a decreased efficacy of Etanercept, suggesting NFKB inhibition as an alternative approach to inhibit cancer cell growth in the presence of macrophage crosstalk. -
Suppression of Intratumoral CCL22 by Type I Interferon Inhibits Migration
Published OnlineFirst October 2, 2015; DOI: 10.1158/0008-5472.CAN-14-3499 Cancer Microenvironment and Immunology Research Suppression of Intratumoral CCL22 by Type I Interferon Inhibits Migration of Regulatory T Cells and Blocks Cancer Progression David Anz1,2, Moritz Rapp1, Stephan Eiber1,2, Viktor H. Koelzer1, Raffael Thaler1, Sascha Haubner1, Max Knott1, Sarah Nagel1, Michaela Golic1, Gabriela M. Wiedemann1, Franz Bauernfeind3, Cornelia Wurzenberger1, Veit Hornung3,4, Christoph Scholz5, Doris Mayr6, Simon Rothenfusser1, Stefan Endres1, and Carole Bourquin1,7 Abstract The chemokine CCL22 is abundantly expressed in many tion. Mechanistic investigations indicated that Treg blockade types of cancer and is instrumental for intratumoral recruit- was a consequence of reduced intratumoral CCL22 levels ment of regulatory T cells (Treg), an important subset of caused by type I IFN. Notably, stable expression of CCL22 immunosuppressive and tumor-promoting lymphocytes. In abrogated the antitumor effects of treatment with RLR or this study, we offer evidence for a generalized strategy to TLR ligands. Taken together, our findings argue that type I blunt Treg activity that can limit immune escape and promote IFN blocks the Treg-attracting chemokine CCL22 and thus tumor rejection. Activation of innate immunity with Toll-like helps limit the recruitment of Treg to tumors, a finding with receptor (TLR) or RIG-I–like receptor (RLR) ligands prevented implications for cancer immunotherapy. Cancer Res; 75(21); 1– accumulation of Treg in tumors by blocking their immigra- 11. Ó2015 AACR. Introduction effector T-cell function ex vivo (1). Indeed, suppression of anti- cancer immunity is mediated predominantly by intratumoral Treg The chemokine CCL22 is abundantly expressed in the tissue of that suppress CD8 T-cell responses locally at the tumor site (6). -
HIV-1-Suppressive Factors Are Secreted by CD4 T Cells During
HIV-1-suppressive factors are secreted by CD4؉ T cells during primary immune responses Sayed F. Abdelwahab*†, Fiorenza Cocchi*†, Kenneth C. Bagley*‡, Roberta Kamin-Lewis*†, Robert C. Gallo*†, Anthony DeVico*†, and George K. Lewis*†§ *Institute of Human Virology, University of Maryland Biotechnology Institute, and Departments of †Microbiology and Immunology and ‡Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD 21201 Contributed by Robert C. Gallo, August 8, 2003 CD4؉ T cells are required for immunity against many viral infec- system faithfully mimics the early stages of the antigen-specific tions, including HIV-1 where a positive correlation has been ob- response of naı¨ve human CD4ϩ T cells, including clonal activa- served between strong recall responses and low HIV-1 viral loads. tion, expansion, contraction, and maintenance (unpublished Some HIV-1-specific CD4؉ T cells are preferentially infected with work and ref. 18). We used this system to study the kinetics of HIV-1, whereas others escape infection by unknown mechanisms. production of HIV-1-suppressive factors against both CXCR4 One possibility is that some CD4؉ T cells are protected from (X4) and CCR5 (R5) viruses. CD4ϩ T cells, starting as naı¨ve cells infection by the secretion of soluble HIV-suppressive factors, al- and differentiating in response to different antigens, secreted though it is not known whether these factors are produced during factors that inhibited both HIV-1IIIB (X4) and HIV-1BaL (R5). primary antigen-specific responses. Here, we show that soluble The anti-X4 factor is predominantly the CC chemokine CCL22 suppressive factors are produced against CXCR4 and CCR5 isolates (macrophage-derived chemokine), whereas the anti-R5 factors -of HIV-1 during the primary immune response of human CD4؉ T are CCL3 (macrophage inflammatory protein-1␣), CCL4 (mac cells.